COPENHAGEN, Denmark – 2nd November 2007 – Santaris Pharma A/S today announced the initiation of an open-label, non-randomized Phase 1 study with its HIF-1 alpha antagonist (EZN-2968) licensed outside Europe in 2006 to Enzon Pharmaceuticals, Inc. USA. The study is designed to evaluate the safety, tolerability, and pharmacokinetics of the HIF-1 alpha antagonist in a daily for 5 days schedule in approximately 30 patients with advanced solid tumors or lymphoma.
